Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37R (line 29) mice: implications for the assessment of putative therapeutic agents

详细信息    查看全文

• 作者：Pierre Zwiegers ; Grace Lee…
• 关键词：SOD1 ; ALS ; Copy number variation ; G93A ; G37R
• 刊名：Journal of Negative Results in BioMedicine
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：13
• 期：1
• 全文大小：682 KB
• 参考文献：1. Byrne, S, Walsh, C, Lynch, C, Bede, P, Elamin, M, Kenna, K, McLaughlin, R, Hardiman, O (2011) Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 82: pp. 623-627 CrossRef
  2. Amyotrophic Lateral Sclerosis Online Genetic Database [http://alsod.iop.kcl.ac.uk/Overview/gene.aspx?gene_id=SOD1]
  3. Saccon, R, Bunton-Stasyshyn, R, Fisher, E, Fratta, P (2013) Is SOD1 loss of function involved in amyotrophic lateral sclerosis?. Brain 136: pp. 2342-2358 CrossRef
  4. Kabashi, E, Valdmanis, P, Dion, P, Rouleau, G (2007) Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis?. Ann Neurology 62: pp. 553-559 CrossRef
  5. Kato, S (2008) Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol 115: pp. 97-114 CrossRef
  6. Joyce, P, Fratta, P, Fisher, E, Acevedo-Arozena, A (2011) SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 22: pp. 420-448 CrossRef
  7. Gurney, M (1997) The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 152: pp. S67-S73 CrossRef
  8. Lee, G, Shaw, CA (2012) Early exposure to environmental toxin contributes to neuronal vulnerability and axonal pathology in familial ALS. Neurosci Med 3: pp. 404-417 CrossRef
  9. Gurney, ME, Pu, H, Chiu, AY, Dal Canto, MC, Polchow, CY, Alexander, DD, Caliendo, J, Hentati, A, Kwon, YW, Deng, HX, Chen, W, Zhai, P, Sufit, RL, Siddique, T (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: pp. 1772-1775 CrossRef
  10. Wong, P, Pardo, C, Borchelt, D, Lee, M, Copeland, N, Jenkins, N, Sisodia, S, Cleveland, D, Price, D (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: pp. 1105-1116 CrossRef
  11. Bruijn, L, Becher, M, Lee, M, Anderson, K, Jenkins, N, Copeland, N, Sisodia, S, Rothstein, J, Borchelt, D, Price, D, Cleveland, D (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: pp. 327-338 CrossRef
  12. Jonsson, P, Graffmo, K, Br?nnstr?m, T, Nilsson, P, Andersen, P, Marklund, S (2006) Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1. J Neuropathol Exp Neurol 65: pp. 1126-1136
  13. Dal Canto, M, Gurney, M (1994) Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 145: pp. 1271-1279
  14. Dal Canto, M, Gurney, M (1995) Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 676: pp. 25-40
  15. Chui, A, Zhai, P, Dal Canto, M, Peters, T, Kwon, Y, Prattis, S, Gurney, M (1995) Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 6: pp. 349-362 CrossRef
  16. Zhang, B, Tu, P, Abtahian, F, Trojanowski, J, Lee, V (1997) Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol 139: pp
• 刊物主题：Biomedicine general;
• 出版者：BioMed Central
• ISSN：1477-5751

文摘

Background In vivo animal models of familial amyotrophic lateral sclerosis (fALS) are widely used to delineate the potential role that genetic mutations play in the neurodegenerative process. While these models are extensively used for establishing the safety and efficacy of putative therapeutics during pre-clinical development, effective clinical translation of pharmacological interventions has been largely unsuccessful. Results In this report we compare a recent cohort of G37R (line 29) mice generated from mating wild-type females with transgenic males obtained commercially to a previous set of offspring produced with transgenic male breeders from a colony established at a local collaborator’s facility. Commercially derived progeny presented with a tightly clustered genomic signature for the mutant human superoxide dismutase1 transgene (hSOD1) locus, and exhibited a greater than two-fold reduction in the number of transgene copies present in the genome compared to offspring derived locally. Decrease in transgene levels corresponded with delayed ALS progression and a significant increase in overall lifespan (146%). Conclusions These results highlight some key challenges inherent to the use of G37R (line 29) animals in pre-clinical studies for the development of ALS therapeutics. Without stringent assessment of mutant SOD1 copy number/protein levels, heterogeneity of transgene levels within cohorts may influence the behavioural and pathological presentation of disease and thus calls to question the validity of any detected therapeutic effects. Nuanced changes in mutant SOD1 copy number that currently remain unreported may undermine research endeavours, delay efforts for clinical translation, and compromise the rigor of animal studies by limiting reproducibility amongst research groups.